Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/10/2020
SIETES contiene 93129 citas

 
 
 1 a 20 de 278 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Anónimo. Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA eequests withdrawal of weight-loss drug. U.S. Food and Drug Administration 2020:13 de febrero. [Ref.ID 103523]
2.Enlace a cita original Cita con resumen
DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ 2017;357:j1455. [Ref.ID 101540]
4.Enlace a cita originalTiene citas relacionadas
Baigent C. Aspirin for disease prevention: public policy or personal choice?. Ann Intern Med 2016;164:846-7. [Ref.ID 100467]
5.Enlace a cita originalTiene citas relacionadas
Bibbins-Domingo K, on behalf of the U.S. Preventive Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:836-45. [Ref.ID 100466]
6.Enlace a cita originalTiene citas relacionadas
Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:826-35. [Ref.ID 100465]
7.Enlace a cita originalTiene citas relacionadas
Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DSM, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:814-25. [Ref.ID 100464]
8.Enlace a cita originalTiene citas relacionadas
Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:804-13. [Ref.ID 100463]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP. Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:777-86. [Ref.ID 100462]
10. Cita con resumen
Friis S, Riis AH, Erichsen R, Baron JA, Sorensen HT. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann Intern Med 2015;163:347-55. [Ref.ID 99513]
11.Enlace a cita original Cita con resumen
Hawkes N. NHS England drops 16 medicines from Cancer Drugs Fund. BMJ 2015;351:h4803. [Ref.ID 99469]
12. Cita con resumen
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, García-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz H-J, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, for the RECOURSE Study Group. Randomized trial of TAS-102 for refractory. N Engl J Med 2015;372:1909-19. [Ref.ID 99139]
13. Cita con resumen
Simkens LHJ, van Tinteren H, May A, ten Tije A, Creemers G-JM, Loosveld OJL, de Jongh FE, Erdkamp FLG, Erjavez Z, van der Torren AME, Tol J, Braun HJJ, Nieboer P, van der Hoeven JJM, Haasjes JG, Jansen RLH, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJA, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015;385:1843-52. [Ref.ID 99088]
14. Cita con resumen
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014;383:1490-502. [Ref.ID 97540]
15. Cita con resumen
Corley DA, Jensen ChD, Marks AR, Zhao WK, Lee JK, Doubeni ChA, Zauber AG, de Boer J, Fireman BH, Schottinger JE, Quinn VP, Ghai NR, Levin TR, Quesenberry ChP. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298-306. [Ref.ID 97371]
16.Enlace a cita originalTiene citas relacionadas
Bonovas S, Nikolopoulos G, Bagos P. Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2013;76:329-37. [Ref.ID 96033]
17.Enlace a cita originalTiene citas relacionadas
Ma J, Gao S, Ni X, Chen F, Liu X, Xie H, Yin H, Lu C. Exposure to bisphosphonates and risk of colorectal cancer. Br J Clin Pharmacol 2013;76:320-8. [Ref.ID 96032]
18.Tiene citas relacionadas
19.Tiene citas relacionadas
Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013;309:2563-71. [Ref.ID 95729]
20.Tiene citas relacionadas Cita con resumen
Burn J, Mathers JC, Bishop DT. Does aspirin really reduce the risk of colon cancer?. Lancet 2012;379:1587. [Ref.ID 92735]
Seleccionar todas
 
 1 a 20 de 278 siguiente >>